中国报告大厅网讯,心血管疾病作为全球主要健康威胁之一,在中国呈现高发态势。针对复杂血管病变的微创介入治疗技术近年来快速发展,为患者提供了更精准、安全的解决方案。近日,国内医疗器械企业先健科技宣布其自主研发的核心产品正式获得国家药监局批准,标志着我国在主动脉腔内修复领域取得重要进展。 一、填补行业空白:首款开窗技术专用支架系统获批 中国报告大厅发布的《2025-2030年中国医药行业竞争格局及...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.